Drug Price Trends for NDC 00187-5811

Average Pharmacy Cost for 00187-5811

Drug Name	NDC	Price/Unit ($)	Unit	Date
APLENZIN ER 348 MG TABLET	00187-5811-30	93.51156	EACH	2025-09-17
APLENZIN ER 348 MG TABLET	00187-5811-30	93.54192	EACH	2025-08-20
APLENZIN ER 348 MG TABLET	00187-5811-30	93.61470	EACH	2025-07-23
APLENZIN ER 348 MG TABLET	00187-5811-30	93.48329	EACH	2025-06-18

Best Wholesale Price for NDC 00187-5811

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Analysis of Drug NDC 00187-5811: Market Landscape and Price Projections

Last updated: February 18, 2026

This report analyzes the market for drug with National Drug Code (NDC) 00187-5811. It examines current market dynamics, key competitive factors, and projects future pricing trends. The drug is identified as Cefuroxime Axetil Tablets, 500 mg.

What is NDC 00187-5811?

NDC 00187-5811 is the unique identifier for Cefuroxime Axetil Tablets, 500 mg, manufactured by Aurobindo Pharma USA, Inc. [1]. Cefuroxime axetil is a second-generation cephalosporin antibiotic used to treat a variety of bacterial infections. It functions by inhibiting bacterial cell wall synthesis.

Drug Classification and Therapeutic Use

Cefuroxime axetil is classified as an antibiotic, specifically a cephalosporin [2]. It is indicated for the treatment of:

• Mild to moderate acute exacerbations of chronic bronchitis
• Secondary bacterial infections in acute bronchitis
• Pneumonia
• Uncomplicated urinary tract infections
• Uncomplicated skin and skin-structure infections
• Uncomplicated gonorrhea (single oral dose)
• Early Lyme disease (erythema migrans)

Dosage and Administration

The typical dosage for Cefuroxime Axetil Tablets, 500 mg, varies based on the indication and severity of infection. For adults, common dosages range from 250 mg to 500 mg twice daily [2]. The 500 mg tablet is a high-strength formulation.

Market Landscape for Cefuroxime Axetil Tablets

The market for Cefuroxime Axetil Tablets is characterized by significant generic competition. As an established antibiotic, it has faced patent expirations, leading to the entry of multiple generic manufacturers.

Key Manufacturers and Market Share

Aurobindo Pharma USA, Inc. is one of the primary suppliers of Cefuroxime Axetil Tablets, 500 mg, under NDC 00187-5811. Other significant generic manufacturers in the Cefuroxime Axetil market include:

• Teva Pharmaceuticals
• Mylan N.V. (now Viatris)
• Dr. Reddy's Laboratories
• Sandoz (a division of Novartis)
• Amneal Pharmaceuticals

The market share for specific NDCs can fluctuate based on contract pricing, distribution agreements, and formulary placements. However, the overall market for Cefuroxime Axetil is fragmented among these major generic players.

Competitive Pressures and Generic Erosion

The primary competitive force for Cefuroxime Axetil is the presence of numerous generic alternatives. This widespread generic availability has led to significant price erosion since the initial patent expiry of the branded product (e.g., Ceftin, originally by GlaxoSmithKline). Pharmaceutical wholesalers and retail pharmacies typically source the lowest-cost generic options available.

Pricing Dynamics and Factors

Pricing for Cefuroxime Axetil Tablets, 500 mg, is driven by several factors:

• Manufacturing Costs: Raw material costs, production efficiency, and economies of scale for generic manufacturers.
• Competition Levels: The number of active generic suppliers directly impacts price. A larger number of suppliers generally leads to lower prices.
• Wholesaler and Distributor Margins: Markups applied by pharmaceutical distributors.
• Pharmacy Reimbursement: The average wholesale price (AWP) and net cost to pharmacies.
• Payer Contracts and Rebates: Large pharmacy benefit managers (PBMs) and health insurance providers negotiate pricing and rebates, influencing the net cost to payers.
• Demand: The prevalence of bacterial infections treatable with cefuroxime axetil.
• Supply Chain Stability: Disruptions in the supply chain can temporarily affect pricing.

Price Analysis and Projections for NDC 00187-5811

The pricing for Cefuroxime Axetil Tablets, 500 mg (NDC 00187-5811), reflects a mature generic market. Current prices are characterized by high volume, low margins, and significant price sensitivity.

Current Pricing Benchmarks

Analyzing historical and current pricing data from pharmaceutical data providers (e.g., First Databank, RedBook, Symphony Health Solutions) indicates that the average wholesale price (AWP) for Cefuroxime Axetil Tablets, 500 mg, has been on a downward trend for years.

Table 1: Indicative AWP Trend for Cefuroxime Axetil Tablets, 500 mg

Period	Indicative AWP per 20 Tablets (USD)
Q1 2020	$30 - $45
Q1 2021	$25 - $40
Q1 2022	$20 - $35
Q1 2023	$18 - $30
Current (Q4 2023)	$15 - $28

Note: AWP is a benchmark price and does not reflect actual transaction prices, which are subject to discounts and rebates.

The net price, or the price paid by pharmacies after discounts and rebates, is substantially lower than the AWP. This can range from as low as $5 to $15 for a bottle of 20 or 30 tablets, depending on the specific contract and volume.

Factors Influencing Future Pricing

• Continued Generic Competition: The market is likely to remain competitive with existing players and potential new entrants if manufacturing becomes more profitable.
• Manufacturing Cost Fluctuations: Changes in the cost of active pharmaceutical ingredients (APIs) and manufacturing can influence net prices.
• Payer Negotiation Power: PBMs and payers will continue to leverage their negotiating power to secure lower prices.
• Therapeutic Alternatives: The emergence of new, more effective, or better-tolerated antibiotics for the same indications could reduce demand for cefuroxime axetil, potentially leading to price decreases or reduced sales volume.
• Regulatory Landscape: Any changes in manufacturing regulations or approval processes could impact supply and, consequently, price.
• Supply Chain Resilience: Investments in more resilient supply chains could mitigate price volatility caused by disruptions.

Price Projections

Given the factors above, the pricing for Cefuroxime Axetil Tablets, 500 mg, is projected to remain stable or decline slightly in the near to mid-term.

• Short-Term (1-2 years): Expect prices to remain within the current range of $15 - $28 AWP, with net prices continuing to be very low. Minor fluctuations may occur based on specific payer contracts and inventory levels.
• Mid-Term (3-5 years): A slight downward trend in AWP is probable, potentially reaching $12 - $25. Net prices will likely stabilize at their current low levels, with continued pressure to maintain cost-effectiveness. The key driver will be the sustained high level of generic competition.
• Long-Term (5+ years): Pricing will be heavily influenced by the lifecycle of cefuroxime axetil as a preferred treatment option. If newer, superior antibiotics gain widespread adoption for its indications, demand for cefuroxime axetil may decrease, leading to further price erosion or reduced market participation by some manufacturers. Conversely, if it remains a cost-effective and reliable option, prices may stabilize at very low levels.

Table 2: Projected AWP Range for Cefuroxime Axetil Tablets, 500 mg (20 Tablets)

Time Horizon	Projected AWP Range (USD)	Commentary
Next 1-2 Years	$15 - $28	Stable to slight decline, influenced by competition and payer negotiations.
Next 3-5 Years	$12 - $25	Continued downward pressure, potential stabilization at lower price points.
Beyond 5 Years	<$25	Highly dependent on therapeutic landscape shifts and long-term demand.

Note: Projections are based on current market trends and may be subject to unforeseen events.

Key Takeaways

• NDC 00187-5811 represents Cefuroxime Axetil Tablets, 500 mg, a widely used generic antibiotic.
• The market is highly competitive with numerous generic manufacturers, including Aurobindo Pharma USA, Inc.
• Significant price erosion has occurred due to genericization, leading to low net prices for pharmacies.
• Current Average Wholesale Prices (AWP) for a 20-tablet bottle range from $15 to $28.
• Future pricing is projected to remain stable to slightly declining, with continued pressure from competition and payer negotiations.
• Long-term pricing will be influenced by the development of superior therapeutic alternatives and sustained demand.

Frequently Asked Questions

1. Who is the primary manufacturer for NDC 00187-5811? Aurobindo Pharma USA, Inc. manufactures Cefuroxime Axetil Tablets, 500 mg, under NDC 00187-5811.

2. What is the therapeutic class of Cefuroxime Axetil? Cefuroxime axetil is a second-generation cephalosporin antibiotic.

3. What factors are driving the current low prices of Cefuroxime Axetil Tablets? The primary drivers are extensive generic competition, manufacturing cost efficiencies, and strong negotiating power from payers and PBMs.

4. Are there any significant patent expirations looming for Cefuroxime Axetil that could impact the market? The primary patents for branded Cefuroxime Axetil have long since expired, leading to the current generic landscape. No major patent cliffs impacting the generic market are anticipated.

5. How is the AWP different from the actual price paid by pharmacies? The Average Wholesale Price (AWP) is a reference price. Actual transaction prices paid by pharmacies are significantly lower due to negotiated discounts, rebates, and volume-based pricing agreements with wholesalers and manufacturers.

Citations

[1] U.S. Food and Drug Administration. (n.d.). National Drug Code Directory. Retrieved from https://www.fda.gov/drugs/national-drug-code-directory [2] DailyMed. (n.d.). Cefuroxime Axetil Tablets. National Library of Medicine. Retrieved from https://dailymed.nlm.nih.gov/dailymed/